Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One-Time iron infusion may speed up mobility recovery in hip fracture patients

NCT ID NCT06898814

Symptom relief Sponsor: Soren Overgaard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single intravenous dose of iron (ferric derisomaltose) can improve mobility recovery in elderly patients after hip fracture surgery. Researchers will compare the iron group to a placebo group in 210 participants across three Danish hospitals. The main goal is to see if the treatment helps patients regain their pre-fracture walking ability, reduce fatigue, and improve blood counts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ferric Derisomaltose (intravenous iron)
What this could lead to
If it works, this could offer a simple, one-time treatment to help elderly patients regain walking ability faster after hip fracture surgery.
What could go wrong
This is a Phase 4 trial, but the benefit may be modest or not apply to all patients. Risks include allergic reactions to iron, and the study is only in Denmark.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 65 years of age or older 2. Acute proximal femur fracture surgery 3. A hemoglobin measurement ≤6.5 mmol/L (10.5 g/dL) on day 1 to 5 postoperatively 4. Independent prefracture indoor walking ability, indoor NMS ≥ 2 5. Ability to speak and understand Danish 6. Able to provide informed consent on the participants own behalf Exclusion Criteria: 1. Known allergy to intravenous iron 2. Residing permanently at a nursing home 3. Hematological conditions with a risk of iron overload e.g. haemochromatosis, hemosiderosis, or where alternative treatments are necessary e.g. haematological malignancies 4. Other contraindication to iron treatment, e.g. severe liver cirrhosis and hepatitis 5. Severe uncontrolled infection as assessed by the responsible clinician (e.g. bacteraemia or sepsis) 6. Plasma sodium levels below 125 or above 150 mmol/L on the day of inclusion 7. Renal replacement therapy 8. Severe dementia assessed by physician 9. Recent intravenous iron injection, 4 weeks prior to surgery 10. Patient declared terminally ill 11. Pathologic Fracture

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia hip fracture

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Hip fracture

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Orthopaedic Surgery, Odense and Svendborg University Hospital

    RECRUITING

    Odense C, 5000, Denmark

  • Department of Orthopedic Surgery and Traumatology, Bispebjerg, Copenhagen University Hospital

    ACTIVE_NOT_RECRUITING

    Copenhagen NV, 2400, Denmark

  • Department of Orthopedic Surgery and Traumatology, Herlev, Copenhagen University Hospital

    RECRUITING

    Herlev, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.